AU2018351006B2 - Anti-CD47 agent-based ovarian cancer therapy - Google Patents
Anti-CD47 agent-based ovarian cancer therapy Download PDFInfo
- Publication number
- AU2018351006B2 AU2018351006B2 AU2018351006A AU2018351006A AU2018351006B2 AU 2018351006 B2 AU2018351006 B2 AU 2018351006B2 AU 2018351006 A AU2018351006 A AU 2018351006A AU 2018351006 A AU2018351006 A AU 2018351006A AU 2018351006 B2 AU2018351006 B2 AU 2018351006B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- dose
- agent
- tumor
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573835P | 2017-10-18 | 2017-10-18 | |
| US62/573,835 | 2017-10-18 | ||
| PCT/US2018/056441 WO2019079548A1 (en) | 2017-10-18 | 2018-10-18 | OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018351006A1 AU2018351006A1 (en) | 2020-05-07 |
| AU2018351006B2 true AU2018351006B2 (en) | 2024-08-29 |
Family
ID=64267915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018351006A Active AU2018351006B2 (en) | 2017-10-18 | 2018-10-18 | Anti-CD47 agent-based ovarian cancer therapy |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11802153B2 (enExample) |
| EP (2) | EP3697817B1 (enExample) |
| JP (2) | JP7308191B2 (enExample) |
| KR (1) | KR102776457B1 (enExample) |
| CN (2) | CN111247172B (enExample) |
| AU (1) | AU2018351006B2 (enExample) |
| CA (1) | CA3078253A1 (enExample) |
| ES (2) | ES2989007T3 (enExample) |
| PL (2) | PL3697817T3 (enExample) |
| PT (2) | PT4177270T (enExample) |
| SI (2) | SI3697817T1 (enExample) |
| WO (1) | WO2019079548A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114716552B (zh) | 2016-01-11 | 2024-05-24 | 四十七公司 | 人源化、小鼠或嵌合抗cd47单克隆抗体 |
| CN111247172B (zh) | 2017-10-18 | 2023-11-14 | 四十七公司 | 基于抗cd47剂的卵巢癌疗法 |
| EP4129336B1 (en) | 2018-02-12 | 2025-05-07 | Forty Seven, LLC | Anti-cd47 agent-based treatment of cd20-positive cancer |
| WO2020047651A1 (en) * | 2018-09-04 | 2020-03-12 | Trillium Therapeutics Inc. | Cd47 blockade with parp inhibition for disease treatment |
| US11702474B2 (en) | 2019-12-17 | 2023-07-18 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
| US20230081265A1 (en) * | 2020-04-06 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody formulation |
| US20230014026A1 (en) * | 2020-06-22 | 2023-01-19 | Morphosys Ag | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint |
| TW202241494A (zh) * | 2021-02-10 | 2022-11-01 | 大陸商同潤生物醫藥(上海)有限公司 | 治療腫瘤的方法和組合 |
| BR112023018450A2 (pt) * | 2021-04-14 | 2023-11-07 | Akeso Biopharma Inc | Anticorpo monoclonal anti-cd47 e seu uso |
| TW202317183A (zh) * | 2021-06-10 | 2023-05-01 | 日商小野藥品工業股份有限公司 | 藉由併用ｃｄ４７抑制物質、免疫檢查點抑制物質及標準療法之癌症治療法 |
| CN115245516A (zh) * | 2021-12-31 | 2022-10-28 | 郑州大学第一附属医院 | 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法 |
| WO2023172643A1 (en) * | 2022-03-08 | 2023-09-14 | Whitehead Institute For Biomedical Research | The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer |
| TWI876305B (zh) * | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3056515T4 (da) | 2008-01-15 | 2025-10-20 | Univ Leland Stanford Junior | Fremgangsmåde til at manipulere fagocytose medieret af cd47 |
| AU2010295661B2 (en) | 2009-09-15 | 2015-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| WO2011041453A1 (en) | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| ES2616010T3 (es) | 2010-05-14 | 2017-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anticuerpos monoclonales humanizados y quiméricos a CD47 |
| US20140271683A1 (en) | 2010-12-21 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor |
| CN104136037B (zh) | 2012-01-17 | 2018-02-23 | 小利兰·斯坦福大学托管委员会 | 高亲和力SIRP‑α试剂 |
| RU2015122228A (ru) | 2012-12-12 | 2017-01-19 | Васкулокс Инк. | Терапевтические антитела к CD47 |
| AU2014238105B2 (en) | 2013-03-15 | 2018-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-CD47 agents |
| ES2898627T3 (es) | 2013-04-29 | 2022-03-08 | Univ Leland Stanford Junior | Uso de agentes anti-CD47 para mejorar la inmunización |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| SG11201607143UA (en) | 2014-03-11 | 2016-09-29 | Univ Leland Stanford Junior | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| ES2819451T3 (es) | 2014-08-08 | 2021-04-16 | Univ Leland Stanford Junior | Agentes PD-1 de alta afinidad y procedimientos de uso |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| CA2961774C (en) | 2014-10-07 | 2023-05-23 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| CA2959821C (en) | 2014-10-24 | 2024-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| PL3656443T3 (pl) | 2015-01-21 | 2022-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | Zastosowanie agonisty trl i środka anty-cd47 do wzmocnienia fagotocytozy komórek nowotworowych |
| WO2016179399A1 (en) | 2015-05-06 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity cd47 analogs |
| WO2016191305A1 (en) | 2015-05-22 | 2016-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| WO2017019767A1 (en) | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| ES2894335T5 (es) | 2015-08-26 | 2024-06-27 | Univ Leland Stanford Junior | Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune |
| CA2998644A1 (en) * | 2015-09-18 | 2017-03-23 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
| CN115569192A (zh) * | 2015-12-11 | 2023-01-06 | 小利兰·斯坦福大学托管委员会 | 以双重靶向cd47和egfr来治疗癌症 |
| US20190290759A1 (en) | 2015-12-28 | 2019-09-26 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer |
| CN114716552B (zh) | 2016-01-11 | 2024-05-24 | 四十七公司 | 人源化、小鼠或嵌合抗cd47单克隆抗体 |
| WO2017127707A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| US11472878B2 (en) | 2016-04-15 | 2022-10-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer |
| CA3031034A1 (en) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
| WO2018031419A1 (en) | 2016-08-12 | 2018-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens |
| ES2987333T3 (es) | 2016-10-26 | 2024-11-14 | Univ Leland Stanford Junior | Regiones bisagra de inmunoglobulina modificadas para reducir la hemaglutinación |
| US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
| CN111247172B (zh) | 2017-10-18 | 2023-11-14 | 四十七公司 | 基于抗cd47剂的卵巢癌疗法 |
| PL3697819T3 (pl) | 2017-10-18 | 2023-03-06 | Forty Seven, Inc. | Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1 |
| US20210213055A1 (en) | 2018-06-13 | 2021-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis |
| US20220091104A1 (en) | 2018-09-28 | 2022-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy |
| WO2020160285A1 (en) | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| WO2020163692A1 (en) | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
-
2018
- 2018-10-18 CN CN201880068424.8A patent/CN111247172B/zh active Active
- 2018-10-18 PL PL18800381.8T patent/PL3697817T3/pl unknown
- 2018-10-18 JP JP2020522016A patent/JP7308191B2/ja active Active
- 2018-10-18 PT PT221995368T patent/PT4177270T/pt unknown
- 2018-10-18 AU AU2018351006A patent/AU2018351006B2/en active Active
- 2018-10-18 ES ES22199536T patent/ES2989007T3/es active Active
- 2018-10-18 PT PT188003818T patent/PT3697817T/pt unknown
- 2018-10-18 EP EP18800381.8A patent/EP3697817B1/en active Active
- 2018-10-18 EP EP22199536.8A patent/EP4177270B1/en active Active
- 2018-10-18 ES ES18800381T patent/ES2932286T3/es active Active
- 2018-10-18 PL PL22199536.8T patent/PL4177270T3/pl unknown
- 2018-10-18 SI SI201830808T patent/SI3697817T1/sl unknown
- 2018-10-18 WO PCT/US2018/056441 patent/WO2019079548A1/en not_active Ceased
- 2018-10-18 KR KR1020207014145A patent/KR102776457B1/ko active Active
- 2018-10-18 CN CN202311510416.3A patent/CN117771364A/zh active Pending
- 2018-10-18 CA CA3078253A patent/CA3078253A1/en active Pending
- 2018-10-18 US US16/756,673 patent/US11802153B2/en active Active
- 2018-10-18 SI SI201831145T patent/SI4177270T1/sl unknown
-
2022
- 2022-11-22 JP JP2022186406A patent/JP2023018062A/ja active Pending
-
2023
- 2023-09-27 US US18/373,655 patent/US20240150461A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018351006A1 (en) | 2020-05-07 |
| SI3697817T1 (sl) | 2023-01-31 |
| ES2989007T3 (es) | 2024-11-25 |
| CN111247172B (zh) | 2023-11-14 |
| US20200283520A1 (en) | 2020-09-10 |
| EP3697817A1 (en) | 2020-08-26 |
| PL4177270T3 (pl) | 2024-11-18 |
| CA3078253A1 (en) | 2019-04-25 |
| EP4177270B1 (en) | 2024-07-31 |
| WO2019079548A1 (en) | 2019-04-25 |
| US11802153B2 (en) | 2023-10-31 |
| CN117771364A (zh) | 2024-03-29 |
| CN111247172A (zh) | 2020-06-05 |
| EP4177270A1 (en) | 2023-05-10 |
| EP3697817B1 (en) | 2022-10-05 |
| ES2932286T3 (es) | 2023-01-17 |
| JP7308191B2 (ja) | 2023-07-13 |
| KR102776457B1 (ko) | 2025-03-06 |
| KR20200068730A (ko) | 2020-06-15 |
| PL3697817T3 (pl) | 2023-01-23 |
| SI4177270T1 (sl) | 2024-10-30 |
| PT4177270T (pt) | 2024-10-23 |
| PT3697817T (pt) | 2023-01-02 |
| US20240150461A1 (en) | 2024-05-09 |
| JP2023018062A (ja) | 2023-02-07 |
| JP2021500349A (ja) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240150461A1 (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| US20240218077A1 (en) | Anti-cd47 agent-based treatment of cd20-positive cancer | |
| AU2018351007B2 (en) | Treatment of ovarian cancer with anti-CD47 and anti-PD-L1 | |
| HK40092156B (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40092156A (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40036030A (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40036030B (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40086849A (en) | Anti-cd47 agent-based treatment of cd20-positive cancer | |
| HK40029255B (zh) | 基於抗cd47剂的卵巢癌疗法 | |
| HK40029255A (en) | Anti-cd47 agent-based ovarian cancer therapy | |
| HK40043124A (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| HK40043124B (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| HK40029258A (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| HK40036031A (en) | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: FORTY SEVEN, LLC Free format text: FORMER NAME(S): FORTY SEVEN, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |